KOSDAQBiotech & Pharma099190

i-SENS

₩12,550▲ 2.37%2026-11-18 close
Market Cap
₩371.1B
Turnover
₩300M
Volume
20K
Shares out.
29.6M
PER
—
PBR
1.0×
EPS
-₩278
Dividend Yield
0.81%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩100 per share · Prices as of the 2026-11-18 close

01

Report overview

CGM growth versus margin recovery at i-SENS

CGM sales passed KRW 10 billion in a single quarter for the first time and lifted results, but the decline in BGM meter sales and four quarters of cumulative net losses remain open issues.

  1. 1

    CGM revenue reached KRW 10.4 billion in the third quarter of 2026, a quarterly high, and the nine-month total of KRW 28.2 billion already exceeds last year's full-year CGM sales (preliminary, announced November 4, 2026).

  2. 2

    Annual operating profit bottomed at KRW 2.66 billion in 2024 and recovered to KRW 7.89 billion in 2025, still well below the KRW 19.8 billion recorded in 2022.

  3. 3

    Net income attributable to controlling shareholders was negative for two consecutive years from 2024 to 2025, and the company said the 2025 net loss reflected non-cash impairment charges.

  4. 4

    Third-quarter 2026 operating profit rose to KRW 3.8 billion, yet higher non-operating losses from non-cash foreign currency translation and FX losses turned controlling-shareholder net income into a KRW 5.31 billion loss.

  5. 5

    Public insurance listings in Europe and the planned U.S. entry support growth, while early overseas costs and the decline in BGM meter sales are the near-term variables.

02

Business structure

i-SENS is a biosensor company that runs its business around blood glucose self-testing (BGM), continuous glucose monitoring (CGM) and point-of-care testing (POCT) within in vitro diagnostics.

In the third quarter of 2026, blood glucose test strips remained the core revenue source, with securities analysis putting strip sales at KRW 48.2 billion, up 9% year on year. The same analysis showed meter sales at KRW 10.1 billion, down 15%, with weaker new device sales and replacement demand cited as a drag.

The POCT segment grew 22% to KRW 8.2 billion, driven by cartridges for electrolyte and gas analysis. The blood coagulation business brought in KRW 4.3 billion, up 1%, providing a steady revenue base.

CGM sales reached KRW 10.4 billion in the third quarter of 2026, a quarterly high, split into KRW 5.5 billion domestic and KRW 4.9 billion overseas. The flagship CareSens Air was launched in Korea in September 2023 and has since expanded through approvals in Europe under the MDR framework and the U.S. FDA process.

Completion of the second automated line at the Songdo plant raised annual CGM capacity to about 2 million units. The Wonju plant produces roughly 1.4 billion BGM strips a year, according to the company's 2024 sustainability report.

On the customer side, BGM sales are sensitive to U.S. shipment volumes of a Japanese medical device maker that acts as an ODM customer, and BGM sales fell 5.2% year on year in the first quarter of 2026.

In CGM, the company is widening data links with insulin pump makers and digital health firms, while the global market remains concentrated among leading players such as Abbott and Dexcom.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩78.7B₩900M1.2%
2025Q4₩83.7B₩2.1B2.5%
2026Q1₩75.1B₩900M1.2%
2026Q2₩88.7B₩6.6B7.5%
2026Q3₩86.5B₩3.8B4.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩264.8B₩19.8B₩16.1B7.5%5.6%47.5%
2023₩265.1B₩10.9B₩3.7B4.1%1.3%64.4%
2024₩291.1B₩2.7B-₩1.8B0.9%−0.6%72.3%
2025₩315.4B₩7.9B-₩5.1B2.5%−1.6%70.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a filed basis, i-SENS annual revenue rose from KRW 264.8 billion in 2022 to KRW 265.1 billion in 2023 (up 0.1% year on year), KRW 291.1 billion in 2024 and KRW 315.4 billion in 2025. Revenue has grown for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.

Operating profit fell from KRW 19.8 billion in 2022 to KRW 10.9 billion in 2023 and KRW 2.66 billion in 2024, then recovered to KRW 7.89 billion in 2025. Operating margin dropped from 7.5% in 2022 to 0.9% in 2024 before reaching 2.5% in 2025.

The company said that improved profitability at overseas subsidiaries contributed to the rise in consolidated operating profit in its 2025 results.

Net income attributable to controlling shareholders fell 77.0% to KRW 3.71 billion in 2023, turned into a KRW 1.79 billion loss in 2024 and widened to a KRW 5.15 billion loss in 2025.

Net income including non-controlling interests was a KRW 6.69 billion loss in 2025, a larger loss than the controlling-shareholder figure. The company said the 2025 net loss reflected non-cash impairment of an investment in a subsidiary and of goodwill, and was not directly tied to core operating performance.

The debt-to-equity ratio rose from 47.5% in 2022 to 72.3% in 2024 and stood at 70.7% at end-2025. Operating cash flow stayed positive each year, at KRW 6.65 billion in 2022, KRW 23 billion in 2024 and KRW 20.1 billion in 2025.

Quarterly revenue rose from KRW 78.7 billion in the third quarter of 2025 to KRW 88.7 billion in the second quarter of 2026, and the third quarter of 2026 came in at KRW 86.5 billion, down 2.5% from the prior quarter but up 9.8% year on year.

Operating profit was KRW 916 million in the third quarter of 2025, KRW 2.05 billion in the fourth quarter, KRW 937 million in the first quarter of 2026, KRW 6.61 billion in the second quarter and KRW 3.8 billion in the third quarter of 2026.

The company said the first quarter of 2026 carried about KRW 3 billion of selling and administrative costs for the U.S. entry and global CGM expansion.

Net income attributable to controlling shareholders was a KRW 8.22 billion loss in the fourth quarter of 2025, then a KRW 1.96 billion profit in the first quarter of 2026 and KRW 3.93 billion in the second quarter, before a KRW 5.31 billion loss in the third quarter of 2026.

In the third quarter, non-operating losses from non-cash foreign currency translation and FX losses drove the swing to a loss, even though gross margin reached 39.9%, up 3.1 points. Over the last four quarters, the controlling-shareholder net loss totals KRW 7.65 billion.

05

Industry analysis

The global CGM market has been described in news coverage as growing on the back of rising diabetes prevalence and a shift in how glucose is measured. One report projected that the global CGM market would grow at a compound annual rate of 16.5%, from about USD 8.9 billion in 2023 to about USD 18.9 billion in 2028.

The same report said Abbott with 56%, Dexcom with 38% and Medtronic with 6% dominate the market. The United States accounts for about half of the global CGM market, so the timing of U.S. entry is a key variable for the scale of the business.

The company presents CareSens Air's MARD accuracy of 9.82% and a wear period of up to 15 days as competitive strengths. Industry observers have also pointed to a U.S. recall of some competitor products over high-glucose misreadings as support for the relative competitiveness of the next-generation product.

Mirae Asset Securities said the CGM market expansion potential is large, but early overseas entry costs and market competition weigh on the business. Traditional BGM demand is stable, but analysts see limits to its growth rate.

The POCT business is becoming a diversification pillar, supported by demand for quick test results at hospitals and clinics. i-SENS CGM results will depend on how fast reimbursement listings and country launches expand in Europe and beyond.

06

Outlook

The company manages an internal target of about KRW 40 billion in CGM revenue for 2026, a target that depends on country approvals and an expanded production and supply base.

Nine-month CGM revenue reached KRW 28.2 billion, and the company said the third-quarter results raised the likelihood of meeting the annual target. Earlier in 2026, the company said about 60% of 2026 CGM revenue was expected to come from overseas.

Overseas, the company entered Bosnia in August 2026 and Saudi Arabia in October 2026, and in the first half secured a supply base in Europe through public insurance listings in Germany, the United Kingdom and Belgium.

The company said European sales ramp up about six months after insurance coverage takes effect, and it expects growth centered on Germany to pick up from 2027. The next-generation CGM, CareSens Air 2, has been submitted for approval by Korea's MFDS, and a U.S. launch depends on approval of this product.

According to press reports, the company has pointed to a 2027 U.S. launch. Clinical costs are rising, and the company expects annual clinical spending of about KRW 15 billion in 2026. The company has also said it would move to quarterly earnings announcements starting from the first quarter of 2026.

The next points to confirm are whether CGM revenue approaches the KRW 40 billion target and whether approval and U.S. launch timing line up.

07

Valuation

PER
—
PBR
1.0×
ROE
-2.3%
EPS
-₩278
BPS
₩11,861
Dividend per share
₩100

The price-to-earnings ratio cannot be calculated because the last four quarters show a net loss. On a price-to-book basis, the share price sits close to the book value attributable to controlling shareholders, so it does not carry a large premium over net assets.

Annual operating profit recovered to KRW 7.89 billion in 2025 but remains under half of the KRW 19.8 billion recorded in 2022, so earnings power is low compared with the earlier peak. Controlling-shareholder net income was KRW 16.1 billion in 2022, but losses since 2024 limit earnings-based multiple comparisons.

At its first-quarter 2026 earnings call, the company said it views its current market capitalization as low compared with global peers. After its third-quarter 2026 results, Mirae Asset Securities kept its Buy rating and presented a target price of KRW 35,000.

The same report said third-quarter operating profit fell short of market expectations. The dividend yield is low relative to the current share price, and cash flow is directed toward CGM capacity expansion and clinical and regulatory spending rather than dividends.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Record quarterly CGM sales and cumulative growth

Third-quarter 2026 CGM sales of KRW 10.4 billion rose 82.4% year on year and 9.8% from the prior quarter, setting a quarterly high. Nine-month CGM sales of KRW 28.2 billion already exceed last year's full-year CGM revenue.

Overseas sales of KRW 4.9 billion account for nearly half of CGM revenue, pointing to a growing overseas-led structure. The company said this raised the likelihood of meeting its annual target.

European reimbursement and an overseas supply base

Public insurance listings in Germany, the United Kingdom and Belgium established a supply base in Europe. The company said sales ramp up about six months after reimbursement takes effect. Entries into Bosnia in August 2026 and Saudi Arabia in October 2026 widened the country footprint. The company attributed part of the CGM growth to the expansion of overseas sales regions.

Signs of improving profitability

Third-quarter 2026 gross margin reached 39.9%, up 3.1 points year on year, and operating margin rose 3.2 points to 4.4%. Quarterly operating profit has been positive in every quarter since the third quarter of 2025. The company said the rise in gross profit outpaced the increase in selling and administrative costs. The company also said gross margin in the first quarter of 2026 held at a firm 42.6%.

09

Bear factors

Decline in BGM meter sales

BGM sales fell 5.2% year on year in the first quarter of 2026, reflecting lower U.S. shipments from a major ODM customer. Third-quarter meter sales also fell 15% to KRW 10.1 billion. How much CGM growth offsets the decline in the core BGM business is central to earnings stability. Mirae Asset Securities said the existing BGM business may have limits to its growth rate.

Slow recovery in operating margin

Third-quarter 2026 operating margin improved to 4.4%, but operating profit fell short of market expectations, according to analysts. The 2025 operating margin of 2.5% remains below the 7.5% recorded in 2022.

Early overseas entry requires upfront spending on distribution and sales bases, which can delay profit improvement, according to analysis. The company expects 2026 annual clinical costs of about KRW 15 billion.

Continued net losses and non-operating swings

Controlling-shareholder net loss swung to KRW 5.31 billion in the third quarter of 2026, driven by non-cash foreign currency translation losses and FX losses. The controlling-shareholder net loss over the last four quarters totals KRW 7.65 billion. The debt-to-equity ratio was 70.7% at end-2025, up from 47.5% in 2022.

The third quarter showed that operating improvement alone does not guarantee a net profit when non-operating items swing.

10

Risk factors

Regulatory and approval

The next-generation CGM CareSens Air 2 has been submitted for MFDS approval, and the U.S. launch plan depends on that process. The 2027 U.S. launch timing cited in press reports could shift with approval timing. A delay would affect the timing of U.S. entry and the pace of overseas CGM expansion.

FX and non-cash losses

Higher non-operating losses were the direct cause of the third-quarter swing to a loss. As overseas sales grow, exchange-rate moves have a larger effect on earnings. In 2025, non-cash impairment of an investment in a subsidiary and of goodwill was reflected in the net loss.

Customer and distribution concentration

BGM quarterly sales have been swayed by U.S. shipment volumes of an ODM customer. CGM depends on distribution partners and country-level reimbursement in a market led by three global players. Volume changes at a single country or customer can have a large effect on quarterly results.

11

What to watch next

  1. Around February 2027

    Preliminary fourth-quarter 2026 results are expected. The 2025 annual preliminary results were announced on February 11, 2026, so a similar timing is likely. Whether fourth-quarter CGM revenue moves the nine-month total of KRW 28.2 billion toward the annual target is the point to confirm.

  2. Late March 2027

    Deadline for the 2026 annual business report, the next regular filing. It will show the audited annual operating profit and net income attributable to controlling shareholders, and the CGM sales figures in the filing.

  3. During 2027

    Whether the next-generation CareSens Air 2 receives MFDS approval and when the U.S. launch takes place. The U.S. is reported to account for about half of the global CGM market, so launch timing will shape the pace of overseas growth.

  4. 2027, after German reimbursement takes effect

    Whether European sales in Germany scale up about six months after reimbursement, as the company expects. The company expects growth centered on Germany to widen from 2027.

12

Overall view

i-SENS grew third-quarter 2026 revenue and operating profit year on year, with CGM sales passing KRW 10 billion in a single quarter for the first time. Nine-month CGM sales of KRW 28.2 billion already exceed last year's full-year CGM revenue, and the company said the chance of meeting its annual target has risen.

Still, BGM meter sales declined, and the 2025 operating margin of 2.5% remains below the 7.5% recorded in 2022.

In the third quarter of 2026, non-cash FX-related losses and other non-operating swings turned controlling-shareholder net income into a KRW 5.31 billion loss, and the last four quarters total a controlling-shareholder net loss of KRW 7.65 billion.

European reimbursement and overseas entry support growth, while early overseas costs and the timing of next-generation product approval remain near-term variables. The share price sits close to book value attributable to controlling shareholders, and brokerage target prices differ from the current share price.

The next points to confirm are the preliminary 2026 fourth-quarter results, the 2026 annual business report and the timing of the U.S. launch.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. alphabiz.co.kr
  2. etoday.co.kr
  3. getnews.co.kr
  4. i-sens.co.kr
  5. i-sens.co.kr
  6. pinpointnews.co.kr
  7. m.news.nate.com
  8. m.news.nate.com
  9. pharm.edaily.co.kr
  10. i-sens.sustainability-report.kr
  11. vegannews.co.kr
  12. kormedi.com
  13. newspim.com
  14. rapportian.com
  15. infostockdaily.co.kr
  16. datanews.co.kr
  17. edaily.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis